View Older Stories View More Recent Stories

May 3, 2018 09:07AM Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home
Apr 20, 2018 07:00AM UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
Apr 5, 2018 07:00AM UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off
Mar 22, 2018 08:00AM CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.
Mar 19, 2018 09:05AM Five Prime Therapeutics (FPRX) Licenses New Drug Target to UCB
Mar 19, 2018 09:00AM Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform
Feb 16, 2018 10:08AM UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)
Jan 8, 2018 01:00AM European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)
Nov 6, 2017 04:44PM Dermira (DERM), UCB Agree to End Collaboration Agreement for CIMZIA
Nov 6, 2017 04:01PM Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
Nov 6, 2017 09:00AM UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting
Nov 6, 2017 08:00AM UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
Sep 15, 2017 01:00AM New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults
Sep 14, 2017 08:04AM Dermira (DERM) Says New CIMZIA Findings Presented at EADV
Sep 14, 2017 08:00AM New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
Sep 11, 2017 04:04PM Amgen (AMGN), UCB Announce EVENITY ARCH Study Results Published in NEJM
Sep 11, 2017 04:00PM EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
Jul 25, 2017 01:00AM UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Jul 17, 2017 06:25AM Amgen (AMGN), UCB Announce FDA CRL for EVENITY BLA to Treat Postmenopausal Women with Osteoporosis
Jul 16, 2017 06:00PM Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
Jun 13, 2017 06:01PM Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy
May 21, 2017 06:01PM Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis
May 18, 2017 12:21PM AGA Campaign to Raise Awareness of Inflammatory Bowel Disease in Patients of Child Bearing Years
Apr 26, 2017 06:25AM UCB Selects Medidata Clinical Cloud® to Support Patient-Centric Drug Development
Apr 21, 2017 12:30PM UCB showcases latest epilepsy research at 2017 Annual Meeting of the American Academy of Neurology
Apr 11, 2017 05:30PM Labor Commissioner Mark Butler Joins Atlanta Businesses at the EFWorks Launch Forum
Apr 11, 2017 07:00AM 1CellBiO Inc announces Collaboration Agreement with UCB
Apr 3, 2017 06:24AM Amgen (AMGN), UCB Phase 2 Study of EVENITY Shows Second Course Led to Significant Increases in Bone Mineral Density
Apr 1, 2017 11:30AM Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)
Mar 15, 2017 07:00AM UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases
Mar 6, 2017 01:00AM First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk
Mar 4, 2017 09:00AM New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
Feb 7, 2017 11:51AM UCB, Inc. and the Epilepsy Foundation of Georgia Launch EFWorks to Help Georgians with Epilepsy Find Employment
Jan 19, 2017 12:00PM UCB files BRIVIACT® (brivaracetam) CV in the U.S. as monotherapy treatment for adult epilepsy patients with partial-onset seizures
Jan 19, 2017 02:00AM Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Jan 5, 2017 09:00AM MC10 and UCB Complete Landmark Pharmaceutical / Technology Collaboration Evaluating Patient Monitoring in Parkinson’s
Dec 19, 2016 07:00PM Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan
Dec 8, 2016 06:18AM Dermira (DERM) Announces CIMZIA Phase 3 Met co-Primary Efficacy Endpoints in Certain Plaque Psoriasis
Dec 8, 2016 02:00AM Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Dec 5, 2016 07:00AM Evogen and UCB Announce Collaboration for Further Development of EvoScore™ START for Improved Diagnosis of Epilepsy
Dec 2, 2016 01:00AM UCB highlights epilepsy research at the 2016 American Epilepsy Society Annual Meeting
Nov 15, 2016 11:00AM The Lancet Publishes First Head-to-Head Study of CIMZIA® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients
Nov 14, 2016 06:55AM Amgen (AMGN), UCB Announce Significant Data from Phase 3 BRIDGE Study for Increasing BMD in Men With Osteoporosis
Nov 12, 2016 04:30PM Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
Nov 11, 2016 07:00AM UCB showcases advancements in its late stage immunology portfolio through innovative research at 2016 ACR/ARHP Annual Meeting
Nov 10, 2016 08:00AM UCB Family Epilepsy Scholarship Program™ Announces 2016 Recipients
Sep 26, 2016 04:01PM Amgen (AMGN), UCB Announce FDA Acceptance of BLA For Romosozumab
Sep 26, 2016 04:00PM Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
Sep 20, 2016 08:00AM UCB Opens Solution Accelerator at Georgia Tech Technology Square
Sep 19, 2016 06:38AM Amgen (AMGN), UCB Announce Significant Data from Romosozumab Phase 3 in Osteoporosis
View More Recent Stories View Older Stories